2September, 2026
Nordicus Partners Corp. (OTCQB: NORD)
Investor Relations
A U.S.-based biotech company acquiring and developing drugs from innovative Nordic biotech companies, dedicated to breakthrough therapeutics for diseases with unmet medical needs, starting with oral disorders.
Begin scrollingQuotes delayed at least 15 minutes. Market data provided by QuoteMedia.
Investor Overview
Developing breakthrough therapeutics for unmet medical needs
Nordicus Partners is the only publicly traded U.S. business accelerator and holding company focused exclusively on empowering Nordic life sciences companies to succeed in the U.S. market. By combining Nordic scientific innovation with U.S. operational expertise, Nordicus targets transformative, scalable opportunities in high-growth life sciences with unmet medical needs.
Its scientific foundation targets inflammation and immune modulation. Current portfolio companies include Orocidin, developing treatments for aggressive periodontal disease; Bio-Convert, focused on preventing oral leukoplakia, a potentially cancerous lesion in the mouth; and NoviThera, developing a novel antibody therapy for psoriasis.
Meet our directors and leadershipStock Information
Full stock informationNORD OTCQB
— —
Portfolio & Pipeline
Explore the portfolioThree Danish subsidiaries advancing first-in-class candidates in inflammation and immune modulation, starting with oral disorders where no approved medical treatment exists today.
Company / CandidateIndicationDiscoveryPreclinicalPhase IIaPhase IIb / IIINext Milestone
Orocidin A/SQR-01Aggressive periodontitisPhase IIa trial in patients planned H1 2027 at the University of Copenhagen
Bio-Convert A/SQR-02 oral gelOral leukoplakia (OLK)GMP manufacturing by December 2026; Phase IIa in Europe H1 2027
NoviThera ApSQR-04 monoclonal antibodyPsoriasisBiological proof of concept established in preclinical study
Status as reported in the Company’s corporate update of June 15, 2026.
Regulatory Filings
All SEC filings| Date | Form | Description | View |
|---|---|---|---|
| Loading the latest filings… | |||
Events & Presentations
Upcoming Events
There are no upcoming events at this time. Sign up for email alerts to be notified of future conference calls, presentations and webcasts.
Past events & presentations
Email Alerts
Stay informed
Receive Nordicus press releases, SEC filings and end-of-day stock prices directly in your inbox.
Contact
Investor Relations
Nordicus Partners Corp.
280 S. Beverly Drive, Suite 505
Beverly Hills, CA 90212
Mail: [email protected]
X: @NordicusIR
Nordic Office
c/o NP Bioinnovation A/S
Vandtårnsvej 62A, 1. E
DK-2860 Søborg, Denmark
Transfer Agent
Transfer Online, Inc.
512 SE Salmon St.
Portland, OR 97214
Tel: +1 503-227-2950
Mail: [email protected]
transferonline.com